TLR3 activation efficiency by high or low molecular mass poly I:C. 2013

Yu Zhou, and Ming Guo, and Xu Wang, and Jielang Li, and Yizhong Wang, and Li Ye, and Ming Dai, and Li Zhou, and Yuri Persidsky, and Wenzhe Ho
Center for Animal Experiment/Animal Biosafety Level III Laboratory and State Key Laboratory of Virology, Wuhan University School of Medicine, Wuhan, Hubei, People's Republic of China.

Toll-like receptor 3 (TLR3) plays a critical role in initiating type I IFN-mediated innate immunity against viral infections. TLR3 recognizes various forms of double stranded (ds) RNA, including viral dsRNA and a synthetic mimic of dsRNA, poly I:C, which has been used extensively as a TLR3 ligand to induce antiviral immunity. The activation efficiency of TLR3 by poly I:C is influenced by various factors, including size of the ligands, delivery methods and cell types. In this study, we examined the stimulatory effect of two commercially-available poly I:Cs [high molecular mass (HMM) and low molecular mass (LMM)] on TLR3 activation in various human cell types by determining the induction of type I and type III IFNs, as well as the antiviral effect. We demonstrated that the direct addition of both HMM- and LMM-poly I:C to the cultures of primary macrophages or a neuroplastoma cell line could activate TLR3. However, the transfection of poly I:C was necessary to induce TLR3 activation in other cell types studied. In all the cell lines tested, the efficiency of TLR3 activation by HMM-poly I:C was significantly higher than that by LMM-poly I:C. These observations indicate the importance and necessity of developing effective TLR3 ligands for antiviral therapy.

UI MeSH Term Description Entries
D007113 Immunity, Innate The capacity of a normal organism to remain unaffected by microorganisms and their toxins. It results from the presence of naturally occurring ANTI-INFECTIVE AGENTS, constitutional factors such as BODY TEMPERATURE and immediate acting immune cells such as NATURAL KILLER CELLS. Immunity, Native,Immunity, Natural,Immunity, Non-Specific,Resistance, Natural,Innate Immune Response,Innate Immunity,Immune Response, Innate,Immune Responses, Innate,Immunity, Non Specific,Innate Immune Responses,Native Immunity,Natural Immunity,Natural Resistance,Non-Specific Immunity
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007372 Interferons Proteins secreted by vertebrate cells in response to a wide variety of inducers. They confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, impede multiplication of intracellular parasites, enhance macrophage and granulocyte phagocytosis, augment natural killer cell activity, and show several other immunomodulatory functions. Interferon
D007378 Interleukins Soluble factors which stimulate growth-related activities of leukocytes as well as other cell types. They enhance cell proliferation and differentiation, DNA synthesis, secretion of other biologically active molecules and responses to immune and inflammatory stimuli. Interleukin
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D009447 Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) Neuroblastomas
D011070 Poly I-C Interferon inducer consisting of a synthetic, mismatched double-stranded RNA. The polymer is made of one strand each of polyinosinic acid and polycytidylic acid. Poly(I-C),Poly(rI).Poly(rC),Polyinosinic-Polycytidylic Acid,Polyinosinic-Polycytidylic Acid (High MW),Polyriboinosinic-Polyribocytidylic Acid,Polyribose Inosin-Cytidil,Inosin-Cytidil, Polyribose,Poly I C,Polyinosinic Polycytidylic Acid,Polyriboinosinic Polyribocytidylic Acid,Polyribose Inosin Cytidil
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral

Related Publications

Yu Zhou, and Ming Guo, and Xu Wang, and Jielang Li, and Yizhong Wang, and Li Ye, and Ming Dai, and Li Zhou, and Yuri Persidsky, and Wenzhe Ho
April 2008, Advanced drug delivery reviews,
Yu Zhou, and Ming Guo, and Xu Wang, and Jielang Li, and Yizhong Wang, and Li Ye, and Ming Dai, and Li Zhou, and Yuri Persidsky, and Wenzhe Ho
June 2009, Respiratory research,
Yu Zhou, and Ming Guo, and Xu Wang, and Jielang Li, and Yizhong Wang, and Li Ye, and Ming Dai, and Li Zhou, and Yuri Persidsky, and Wenzhe Ho
March 2011, The Journal of biological chemistry,
Yu Zhou, and Ming Guo, and Xu Wang, and Jielang Li, and Yizhong Wang, and Li Ye, and Ming Dai, and Li Zhou, and Yuri Persidsky, and Wenzhe Ho
July 2010, Cancer science,
Yu Zhou, and Ming Guo, and Xu Wang, and Jielang Li, and Yizhong Wang, and Li Ye, and Ming Dai, and Li Zhou, and Yuri Persidsky, and Wenzhe Ho
May 2023, The American journal of drug and alcohol abuse,
Yu Zhou, and Ming Guo, and Xu Wang, and Jielang Li, and Yizhong Wang, and Li Ye, and Ming Dai, and Li Zhou, and Yuri Persidsky, and Wenzhe Ho
December 2009, The Journal of experimental medicine,
Yu Zhou, and Ming Guo, and Xu Wang, and Jielang Li, and Yizhong Wang, and Li Ye, and Ming Dai, and Li Zhou, and Yuri Persidsky, and Wenzhe Ho
July 1981, Journal of immunology (Baltimore, Md. : 1950),
Yu Zhou, and Ming Guo, and Xu Wang, and Jielang Li, and Yizhong Wang, and Li Ye, and Ming Dai, and Li Zhou, and Yuri Persidsky, and Wenzhe Ho
January 2008, BMC cancer,
Yu Zhou, and Ming Guo, and Xu Wang, and Jielang Li, and Yizhong Wang, and Li Ye, and Ming Dai, and Li Zhou, and Yuri Persidsky, and Wenzhe Ho
January 2020, Journal of immunology research,
Yu Zhou, and Ming Guo, and Xu Wang, and Jielang Li, and Yizhong Wang, and Li Ye, and Ming Dai, and Li Zhou, and Yuri Persidsky, and Wenzhe Ho
January 2018, Frontiers in immunology,
Copied contents to your clipboard!